Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–7 of 7 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: INCB123667 Clear all
Recruiting Phase 3 Interventional

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCT07214779
View directory record Official record
Conditions
Ovarian Cancer
Interventions
INCB123667, Investigator's choice of chemotherapy
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
48
States / cities
Anchorage, Alaska • Tucson, Arizona • Duarte, California + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 2, 2026, 5:41 AM EDT
Recruiting Phase 2 Interventional

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCT07023627
View directory record Official record
Conditions
Ovarian Cancer
Interventions
INCB123667
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
38
States / cities
Mobile, Alabama • Los Angeles, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 2, 2026, 5:41 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease

NCT07559396
View directory record Official record
Conditions
Renal Impairment
Interventions
INCB123667
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants

NCT07218744
View directory record Official record
Conditions
Healthy Participants
Interventions
INCB123667
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants

NCT06909162
View directory record Official record
Conditions
Healthy Participants
Interventions
INCB123667, itraconazole, carbamazepine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
19 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 2, 2026, 5:41 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment

NCT07559474
View directory record Official record
Conditions
Hepatic Insufficiency, Liver Diseases
Interventions
INCB123667
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Chandler, Arizona • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 2, 2026, 5:41 AM EDT
Active, not recruiting Phase 1 Interventional

Study of INCB123667 in Subjects With Advanced Solid Tumors

NCT05238922
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB0123667, Palbociclib, Bevacizumab, Olaparib, Paclitaxel, Ribociclib, Fulvestrant
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
18
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 2, 2026, 5:41 AM EDT